Medii, Inc.
3 known investors
Runs 'E-consult', an online specialist consultation service connecting primary physicians with expert specialists to help find undiagnosed rare-disease patients.
Also known as Medii · 株式会社Medii
Investors · 3
Also in the syndicate · 1
Company profile
researched Aug 2026Medii, Inc. (株式会社Medii) is a Tokyo-based health-technology company that develops and operates a clinical-question resolution platform for physicians. Its core service, 'Medii E-consult', lets an attending physician who is uncertain about a diagnosis or treatment plan consult expert specialists online; consultations are anonymous for the asking physician, answers are given under the specialist's real name, and the company reports an average response time of about 40 minutes, with the service free of charge for physicians. Alongside E-consult, Medii develops 'Medii Q', an AI search product for doctors that returns evidence from PubMed together with physician answers, and runs '症例バンク' (Case Bank), a service for posting and searching case slides, and 'Medii Magazine', a media property for physicians presenting specialist knowledge.
The company positions its work around problems of specialization and information overload in medicine: rare and intractable diseases are seen infrequently by any individual doctor, expert specialists for a given disease are few and geographically scattered across Japan, and the volume of medical literature and highly specialized drugs continues to grow. Medii states its mission as 'medicine that leaves no one behind' (誰も取り残さない医療を). Its stated business consists of operating the physician-facing clinical question platform and providing marketing support to pharmaceutical companies, described by the company as a loop connecting patients, physicians and pharmaceutical firms.
Founding story
Medii was founded by Hiroki Yamada, a physician who serves as representative director. He has described falling ill at age 14 and waiting nine years for a diagnosis, with four hospital admissions and repeated travel from his home in Wakayama to Osaka for care, before being diagnosed at age 23, while a medical student, with an incurable autoimmune intractable disease. Yamada graduated from Wakayama Medical University's school of medicine and completed graduate medical studies at Keio University (MD, PhD), worked at institutions including St. Luke's International Hospital and Keio University Hospital, and practiced in remote-island medicine as a resident before founding Medii. He is a rheumatology and collagen disease internist, a certified specialist and instructor of the Japan College of Rheumatology, and a certified internist of the Japanese Society of Internal Medicine.
Business model
Medii operates a two-sided model: the physician-facing clinical question platform (E-consult, Medii Q, Case Bank, Medii Magazine) is provided free of charge to doctors, while the company monetizes through marketing support services sold to pharmaceutical companies, particularly in specialty and rare-disease therapeutic areas. The company describes this as a self-reinforcing ecosystem linking patients, physicians and pharmaceutical firms.
Revenue is derived from pharmaceutical-company marketing support rather than from physician users, who use E-consult and the related services at no cost.
Traction
Cumulative consultations on Medii E-consult surpassed 20,000 in December 2025, and total searches on Medii Q exceeded 50,000 in December 2025. The company reported 48 employees as of the end of July 2026 and capital of 100 million yen. Its post-money valuation including potential shares was reported at 3,073 million yen as of 12 February 2024.
Latest developments
Announcements reported in 2025-2026 include the formal release of Medii Q and passing 50,000 total searches (December 2025), Medii E-consult passing 20,000 cumulative consultations (December 2025), system provision to the Sukoyaka Oyako Support Association's online specialist consultation desk for rare and intractable diseases (February 2026), the 'Medii E-consult Award 2025', a seminar for pharmaceutical companies in April 2026, a muscular dystrophy consultation desk (April 2026), collaboration with Asahi Kasei Therapeutics on disseminated intravascular coagulation (May 2026), collaboration with Teijin Pharma in hypoparathyroidism (June 2026), a consultation desk for fibrodysplasia ossificans progressiva (August 2026), and the establishment of an irAE care consortium (CCi) (August 2026).
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Medii describes a network of more than 2,000 expert specialists across all clinical departments, and states that Medii E-consult covers consultations for diseases accounting for 99% of patients with designated intractable diseases in Japan. Named participating experts include department heads and society chairs in rheumatology, hematology, interstitial lung disease and neuroimmunology. Recognition includes the Japan Service Award's Minister of Health, Labour and Welfare Award, the top prize in the Nikkei Awards for Excellent Products and Services, and selection in Weekly Toyo Keizai's 'Amazing Ventures 100' (2023).
The service pairs anonymous questioning by the attending physician with named responses from identified expert specialists, aiming for fast turnaround at no cost to the physician, and combines this human 'narrative' consultation channel with an evidence-search product built on PubMed. Coverage across all clinical departments and a specialist network spanning diseases representing 99% of designated intractable disease patients in Japan is presented as the core asset.
Technology
The platform combines an online consultation and chat workflow matching attending physicians with expert specialists, a mobile application, and AI-based search: Medii Q takes a clinical question and returns evidence drawn from PubMed alongside physician-provided answers, with PMIDs attached for access to source articles. The company also operates a case-slide posting and search database.
Go-to-market
Distribution is through free physician sign-up to the consultation and search products, supported by physician-facing media and case-sharing content, plus disease-specific consultation desks. Commercial reach is extended through tie-ups with pharmaceutical companies and industry partners, integration with third-party clinical software such as the Symview web medical-interview tool, media partnerships, seminars for pharmaceutical companies, and system provision to external bodies such as an association operating a rare and intractable disease online specialist consultation desk.
Primary-care and attending physicians across specialties in Japan who face diagnostic or treatment uncertainty, expert specialists who answer consultations, and pharmaceutical companies marketing specialty and rare-disease treatments. Disease-area consultation desks have been opened for conditions including fibrodysplasia ossificans progressiva and muscular dystrophy.
Geography
Operations are centered on Japan, with headquarters at THE PORTAL Shinjuku Gyoen 4F, 1-23-1 Shinjuku, Shinjuku-ku, Tokyo. The company emphasizes covering regional disparities in access to specialists across Japanese prefectures.
History
The company was established in February 2020 (incorporation date given as 20 February 2020; one investor profile lists founding as January 2020). It released 'Medii E-consult' and carried out a third-party allotment capital increase in June 2020 with the amount undisclosed. In 2023 it was selected for Weekly Toyo Keizai's 'Amazing Ventures 100' list and its founder was named to Forbes Japan's '100 NEXT GENERATION LEADERS'. In 2024 it raised a Series A round led by Globis Capital Partners and received the Minister of Health, Labour and Welfare Award at the Japan Service Awards. In 2025 it formally launched 'Medii Q' and won the top prize in the Nikkei Awards for Excellent Products and Services. Partnership activity has included Nippon Boehringer Ingelheim (2022), Layered (2022), Nikkei BP (2023), and, in 2026, Asahi Kasei Therapeutics and Teijin Pharma.
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 15
launches, deals, and filingsJoint effort targeting early diagnosis and treatment optimization for DIC.
Case consultation window aimed at early diagnosis and treatment optimization in muscular dystrophy.
Formal launch of the AI search product for physicians that returns PubMed evidence and physician answers.
Alliance to accelerate early diagnosis and optimal treatment in rare disease and other specialty areas.
Integration of Layered's web medical interview service 'Symview' with Medii's physician-only online specialist consultation service 'E-consult'.
Tie-up aimed at addressing regional disparities in access to expertise in the interstitial lung disease field.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 6
primary sources listed
- 株式会社Medii｜スピーダ スタートアップ情報リサーチinitial.inc · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Medii, Inc. do?
- Japanese health-tech company operating an online platform where physicians consult expert specialists on difficult and rare-disease cases.
- Who are Medii, Inc.'s investors?
- Medii, Inc.'s investors include Fast Track Initiative, Globis Capital Partners.